Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing